Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-01-01
2008-01-01
Anderson, Rebecca (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S432000
Reexamination Certificate
active
07314886
ABSTRACT:
Provided herein are indole derivatives, pharmaceutical compositions containing them, methods for their use, and methods for preparing these compounds.
REFERENCES:
patent: 3590028 (1971-06-01), Arcamone et al.
patent: 3843681 (1974-10-01), Demerson et al.
patent: 3939178 (1976-02-01), Demerson et al.
patent: 4012448 (1977-03-01), Smith et al.
patent: 4041169 (1977-08-01), Demerson et al.
patent: 4056537 (1977-11-01), Demerson et al.
patent: 4070371 (1978-01-01), Demerson et al.
patent: 4179503 (1979-12-01), Asselin et al.
patent: 4686213 (1987-08-01), Ferdinandi et al.
patent: 4748252 (1988-05-01), Ferdinandi et al.
patent: 5420289 (1995-05-01), Musser et al.
patent: 5561151 (1996-10-01), Young et al.
patent: 5776967 (1998-07-01), Kreft et al.
patent: 5824699 (1998-10-01), Kreft et al.
patent: 5830911 (1998-11-01), Failli et al.
patent: 5955504 (1999-09-01), Wechter et al.
patent: 5972986 (1999-10-01), Seibert et al.
patent: 6025353 (2000-02-01), Masferrer et al.
patent: 6255347 (2001-07-01), Xiaotao et al.
patent: 6545034 (2003-04-01), Carson et al.
patent: 6552055 (2003-04-01), Spiegelman et al.
patent: 6573292 (2003-06-01), Nardella
patent: 7105560 (2006-09-01), Carson et al.
patent: 7105561 (2006-09-01), Carson et al.
patent: 7129262 (2006-10-01), Carson et al.
patent: 7151100 (2006-12-01), Carson et al.
patent: 7189752 (2007-03-01), Carson et al.
patent: 7211599 (2007-05-01), Carson et al.
patent: 2002/0015943 (2002-02-01), Bienz
patent: 2002/0107280 (2002-08-01), McLaren et al.
patent: 2003/0064384 (2003-04-01), Hung et al.
patent: 2006/0293253 (2006-12-01), Carson et al.
patent: 2007/0111950 (2007-05-01), Carsen et al.
patent: 1299577 (1992-04-01), None
patent: 1 436 893 (1976-05-01), None
patent: WO 02/12188 (2002-02-01), None
patent: WO 02/088081 (2002-11-01), None
patent: WO 02/092635 (2002-11-01), None
Kolluri et al. PNAS 2005, 102(7), 2525-2530.
Brenna et al., “New Enzymatic and Chemical Approaches to Enantiopure Etodolac”,Tetrahedron(1997), vol. 53, No. 52, pp. 17769-17780.
Demerson et al., “Chemistry and Antiinflammatory Activities of Prodolic-Acid and Related 1,3,4,9-Tetrahydropyrano[3,4-b]indole-1-alkanoic Acids”,Journal of Medicinal Chemistry(1975), vol. 18, No. 2, pp. 189-191.
Amir et al., 2003, J. Biol. Chem., 278:30828-30834.
Araki et al., “Regulation of Cyclooxygenase-2 Expression by the Wnt and Ras Pathways”, Cancer Research (2003), vol. 63, pp. 728-734.
Baek et al., 2001 Mol. Pharmacol. 59:901-908.
Blaker et al., 1999 Genes Chromosomes Cancer 25:399-402.
Briata et al., Mol. Cell., 12:1201-1211.
Carayol et al., 2002, Am. J. Respir Cell Mol Biol., 26:341-347.
Chan et al., 1999, J. Pharmacol Exp. Ther. 290:551-560.
Chung et al., “Regulation of leukemic cell adhesion, proliferation, and survival by 62 -catenin” 2002 Blood 100:982-990.
Dihlmann et al., “Reduction of β-catenin/T-Cell Transcription Factor Signaling by Aspirin and Indomethacin is Caused by an Increased Stabilization of Phosphorylated β-catenin”, Molecular Cancer Therapeutics, (2003), vol. 2, pp. 509-516.
Dihlmann et al., Oncogene 20:645-653.
Eriksen et al., “NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo”, 2002 J. Clinical Invest. 112:440-449.
Fukuchi et al., 1998 Cancer Res. 58:3526-3528.
Garcia-Rostan et al., 1999 Cancer Res. 59:1811-1815.
He et al., “PPARδ is an APC-Regulated target of Nonsteriodal Anti-Inflammatory Drugs”, 1999 Cell 99:335-345.
Hinz et al., 2002 J. Pharm. Exp. Ther. 300:367-375.
Iwao et al., Jpn. J. cancer Res., 90:205-209.
Korinek et al., “Constitutive Transcriptional Activation by a β-catenin-Tcf Complex in APC-/-Colon Carcinoma” 1997, Science, 275:1784-1787.
Lehmann et al., 1997, J. Biol. Chem., 272:3406-3410.
Li et al., “β-Catenin Signaling”, Cancer Biology and therapy (2002), vol. 1, No. 6, 621-625.
Lim et al., “Significance of E-cadherin/β-catenin complex and cyclin D1 in breast cancer”, Oncology Reports (2002), vol. 9, 915-928.
Lin et al., 2000 Proc. Natl. Acad. Sci., 97:4262-4266.
Mardini et al., “Selective inhibitors of Cyclooxygenase-2: A growing class of anti-inflammatory drugs”, Molecular Inventions (2001), vol. 1, No. 1, 30-38.
McEntee et al., 1999 Carcinogenesis 20:635-640.
Miyoshi et al., “β-catenin: a transforming actor on many stages”, Breast Cancer Research (2003) vol. 5, no. 2, 63-68.
Muthukkauppah et al., 1982, J. Natl. Cancer Inst., 69:699-708.
Noda et al., 2002 J. Gastrointerol. 37(11):896-904.
Ohta et al., 2002 Int. J. Oncol. 21:37-42.
Okamura et al., 2003 Cancer Res. 63:728-734.
Park, Ben Ho et al., “Genetic disruption of PPARδ decreases the tumorigencity of human colon cancer cells”, Proc. Natl. Acad. Sci., (2001), vol. 98, No. 5., pp. 2598-2603.
Polakis, “Wnt signaling and cancer”, 2000 Genes and Development, 14:1837-1851.
Riendeau et al., 1997, Can. J. Physiol. Pharmacol., 75:1088-1095.
Romijn et al., 1988 Prostate 12:99-110.
Rubinfeld et al., 1997 Science 275:1790-1792.
Sakai et al., 2002, Int. J. Oncology 21:547-552.
Sauter et al., “Antisense Cyclin D1 Induces Apoptosis and Tumor Shrinkage in Human Squamous Carcinomas”, Cancer Research (1999), vol. 59, 4876-4881.
Shan et al., J.Pharm. Sci., 86 (7), 765-767.
Shiff et al., “The Role of Cyclooxygenase Inhibition in the Antineoplastic Effects of Nonsteroidal Antiinflammatory Drugs (NSAIDs)”, J. Exp. Med. (1999), vol. 190, No. 4, 445-450.
Shimada et al., 2002 Gut 50:658-664.
Swinney et al., 1997, J. Biol. Chem. 272:12393-12398.
Takayasu et al., 2001, Clin. Cancer Research, 7:901-908.
Tetsu et al., Nature 398:422-426.
Ueta et al., “β-catenin and cyclin D1 expression in human hepatocellular carcinoma” (2002) Oncology Reports 9:1197-1203.
Wakita et al., 2001, Cancer Res., 61:854-858.
Warner et al., 1999, Proc. Natl. Acad. Sci., 96:7563-7568.
Weggen et al., 2001 Nature 414:212-216.
Winter et al., (1962), Proc. Soc. Exp. Biol. Med. 111-544.
Wong et al., “β-catenin-a linchpin in Colorectal Carcinogensis?”, American Journal of Pathology (2002), vol. 160, No. 2, 389-401.
Xu et al., 1994 Int. J. Cancer 59:383-387.
Zhang et al., “Malignant Transformation and Antineoplastic Actions of Nonsteroidal Antiinflammatory Drugs (NSAIDs) on Cyclooxygenase-null Embryo Fibroblasts”, Journal of Experimental Medicine (1999), vol. 190, No. 4, 451-459.
Hedvat et al.,Cancer Cell(2004), vol. 5, pp. 565-574.
Lu et al.,Proc. Natl. Acad. Sci.(2004), vol. 101, No. 9, pp. 3118-3123.
U.S. Appl. No. 11/615,396, filed Dec. 22, 2006, Carson et al.
Chao Qi
Elliott Gary T.
Leoni Lorenzo
Phillips Mimi K.
Anderson Rebecca
Cephalon Inc.
Nolan Jason M
LandOfFree
Tetrahydropyrano-indole derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tetrahydropyrano-indole derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tetrahydropyrano-indole derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2806486